Clinical Edge Journal Scan

Link between reproductive factors and breast cancer incidence


 

Key clinical point: Use of female hormones was associated with an increased incidence of breast cancer (BC) in premenopausal women. Among postmenopausal women, older age at first birth increased the incidence of BC, whereas more births decreased it.

Major finding: Use of female hormones significantly increased the incidence of premenopausal breast cancer (adjusted hazard ratio [aHR], 1.53; P = .03). Incidence of postmenopausal breast cancer was higher in women aged 26 years or more vs. 21-25 years at first birth (aHR, 1.34, 1.47, and 1.68 for ages 26-30, 31-35, and 36 years and older, respectively; P less than .001) and lower in women giving more vs. no births (aHR, 0.85, 0.65, and 0.52 for 1, 2, and 3 and more births, respectively; P = .02).

Study details : Findings are from a pooled analysis of 9 population-based cohort studies conducted in Japan including 187,999 women (premenopausal, n=61,113; postmenopausal, n=126,886).

Disclosures: This study was supported by the National Cancer Center Research and Development Fund and the Health and Labour Sciences Research Grants for the Third Term Comprehensive Control Research for Cancer. The authors had no disclosures.

Source: Takeuchi T et al. Cancer Med. 2021 Mar 1. doi: 10.1002/cam4.3752 .

Recommended Reading

Most breast cancer screening centers not following guidelines
MDedge Hematology and Oncology
Could tamoxifen dose be slashed down to 2.5 mg? 
MDedge Hematology and Oncology
Huge, struggling breast cancer screening trial gets lifeline
MDedge Hematology and Oncology
Risk-based mammography proposed for times of reduced capacity
MDedge Hematology and Oncology
Early breast cancer: Updated MINDACT findings back omitting chemotherapy in low genomic risk
MDedge Hematology and Oncology
Early breast cancer: Updated MINDACT findings back omitting chemotherapy in low genomic risk
MDedge Hematology and Oncology
Pembrolizumab fails to improve OS in patients with previously treated metastatic TNBC
MDedge Hematology and Oncology
Node-negative ER+/HER2− breast cancer: Adjuvant ET improves OS in older patients with comorbidities
MDedge Hematology and Oncology
Advanced breast cancer: Palbociclib+ET associated with low burden of cutaneous toxicities
MDedge Hematology and Oncology
Breast MRI less accurate in predicting nodal status after neoadjuvant therapy in invasive lobular carcinoma
MDedge Hematology and Oncology